Lazard Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2M | Hold |
24,928
| – | – | ﹤0.01% | 892 |
|
|
2025
Q4 | $2.13M | Buy |
24,928
+1,221
| +5% | +$100K | ﹤0.01% | 838 |
|
|
2025
Q3 | $1.84M | Sell |
23,707
-7,665
| -24% | -$599K | ﹤0.01% | 885 |
|
|
2025
Q2 | $2.45M | Buy |
31,372
+23,496
| +298% | +$1.75M | ﹤0.01% | 946 |
|
|
2025
Q1 | $570K | Buy |
7,876
+3,290
| +72% | +$235K | ﹤0.01% | 1371 |
|
|
2024
Q4 | $339K | Sell |
4,586
-913
| -17% | -$63.9K | ﹤0.01% | 1473 |
|
|
2024
Q3 | $362K | Sell |
5,499
-378,615
| -99% | -$27.5M | ﹤0.01% | 1460 |
|
|
2024
Q2 | $35.5M | Buy |
384,114
+290,485
| +310% | +$25.7M | 0.04% | 276 |
|
|
2024
Q1 | $8.95M | Buy |
93,629
+44,257
| +90% | +$3.72M | 0.01% | 562 |
|
|
2023
Q4 | $3.76M | Sell |
49,372
-190,763
| -79% | -$13.3M | ﹤0.01% | 736 |
|
|
2023
Q3 | $16.6M | Sell |
240,135
-232,177
| -49% | -$18.7M | 0.02% | 425 |
|
|
2023
Q2 | $44.6M | Buy |
472,312
+366,597
| +347% | +$31.9M | 0.05% | 227 |
|
|
2023
Q1 | $8.74M | Buy |
105,715
+98,360
| +1,337% | +$7.73M | 0.01% | 612 |
|
|
2022
Q4 | $547K | Sell |
7,355
-280
| -4% | -$21.6K | ﹤0.01% | 1105 |
|
|
2022
Q3 | $630K | Sell |
7,635
-43,281
| -85% | -$4.16M | ﹤0.01% | 1062 |
|
|
2022
Q2 | $4.84M | Buy |
50,916
+44,390
| +680% | +$4.6M | 0.01% | 744 |
|
|
2022
Q1 | $767K | Sell |
6,526
-789
| -11% | -$88.5K | ﹤0.01% | 1039 |
|
|
2021
Q4 | $947K | Sell |
7,315
-19,921
| -73% | -$2.32M | ﹤0.01% | 1012 |
|
|
2021
Q3 | $3.08M | Buy |
27,236
+20,988
| +336% | +$2.4M | ﹤0.01% | 853 |
|
|
2021
Q2 | $646K | Sell |
6,248
-3,755
| -38% | -$354K | ﹤0.01% | 1011 |
|
|
2021
Q1 | $836K | Sell |
10,003
-518,554
| -98% | -$43.8M | ﹤0.01% | 914 |
|
|
2020
Q4 | $48.2M | Sell |
528,557
-76,572
| -13% | -$6.35M | 0.06% | 250 |
|
|
2020
Q3 | $48.3M | Buy |
605,129
+55,101
| +10% | +$4.3M | 0.07% | 223 |
|
|
2020
Q2 | $38M | Buy |
550,028
+182,453
| +50% | +$13M | 0.06% | 229 |
|
|
2020
Q1 | $23.1M | Buy |
367,575
+17,496
| +5% | +$1.26M | 0.04% | 281 |
|
|
2019
Q4 | $27.2M | Buy |
350,079
+275,847
| +372% | +$21.5M | 0.04% | 296 |
|
|
2019
Q3 | $5.44M | Buy |
74,232
+16,689
| +29% | +$1.17M | 0.01% | 538 |
|
|
2019
Q2 | $3.54M | Sell |
57,543
-12,402
| -18% | -$750K | 0.01% | 662 |
|
|
2019
Q1 | $4.46M | Buy |
69,945
+15,891
| +29% | +$907K | 0.01% | 612 |
|
|
2018
Q4 | $2.76M | Sell |
54,054
-78,198
| -59% | -$3.96M | 0.01% | 610 |
|
|
2018
Q3 | $7.67M | Sell |
132,252
-1,203
| -0.9% | -$58.8K | 0.01% | 493 |
|
|
2018
Q2 | $6.47M | Buy |
133,455
+103,365
| +344% | +$4.82M | 0.01% | 523 |
|
|
2018
Q1 | $1.4M | Buy |
30,090
+30,036
| +55,622% | +$1.3M | ﹤0.01% | 678 |
|
|
2017
Q4 | $2K | Hold |
54
| – | – | ﹤0.01% | 1043 |
|
|
2017
Q3 | $1K | Sell |
54
-5,304
| -99% | -$202K | ﹤0.01% | 968 |
|
|
2017
Q2 | $211K | Sell |
5,358
-23,157
| -81% | -$845K | ﹤0.01% | 766 |
|
|
2017
Q1 | $894K | Buy |
+28,515
| New | +$893K | ﹤0.01% | 707 |
|
|
2015
Q4 | – | Sell |
-91,704
| Closed | -$2.17M | – | 1117 |
|
|
2015
Q3 | $2.17M | Sell |
91,704
-127,980
| -58% | -$3.09M | 0.01% | 590 |
|
|
2015
Q2 | $5.21M | Sell |
219,684
-137,184
| -38% | -$3.1M | 0.01% | 514 |
|
|
2015
Q1 | $8.47M | Sell |
356,868
-115,536
| -24% | -$2.59M | 0.02% | 421 |
|
|
2014
Q4 | $10M | Sell |
472,404
-77,664
| -14% | -$1.56M | 0.02% | 401 |
|
|
2014
Q3 | $9.36M | Buy |
+550,068
| New | +$8.68M | 0.02% | 401 |
|
Other funds holding EW
VCM
VPM
Lazard Asset Management's EW Position: Q1 2026 in Review
Lazard Asset Management held its Edwards Lifesciences (EW) position steady in Q1 2026 at 24,928 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #892.
Lazard Asset Management first reported a position in EW in Q3 2014 and has held it in 42 quarters since. The position peaked at $48.3M in Q3 2020. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Lazard Asset Management held 24,928 shares of Edwards Lifesciences worth $2M as of Q1 2026.
- Lazard Asset Management left its Edwards Lifesciences share count unchanged in Q1 2026.
- Edwards Lifesciences made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #892 holding.
- Lazard Asset Management first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 42 quarters since.
- Lazard Asset Management's Edwards Lifesciences position peaked at $48.3M in Q3 2020.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.